Syndax Pharmaceuticals (SNDX) Cash & Current Investments (2015 - 2026)

Syndax Pharmaceuticals' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $352.1 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 122.67% year-over-year to $352.1 million; the TTM figure through Mar 2026 stood at $352.1 million (up 122.67% YoY), while the FY2025 annual figure was $154.5 million, down 5.83% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $352.1 million, up from $154.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $570.7 million in Q4 2023, with the low at $63.3 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $158.1 million (2025), against an average of $251.0 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments plunged 84.09% in 2023, then jumped 586.22% in 2024.
• Syndax Pharmaceuticals' Cash & Current Investments stood at $475.8 million in 2022, then climbed by 19.94% to $570.7 million in 2023, then sank by 71.24% to $164.1 million in 2024, then dropped by 5.83% to $154.5 million in 2025, then jumped by 127.81% to $352.1 million in 2026.
• Business Quant data shows SNDX's Cash & Current Investments at $352.1 million in Q1 2026, $154.5 million in Q4 2025, and $135.0 million in Q3 2025.